Light chain AL amyloidosis is a systemic disorder involving tissue deposition of amyloid fibrils. Often delayed in diagnosis due to nonspecific systemic symptoms, AL amyloidosis must be confirmed on tissue biopsy. Once diagnosis is made, patients can be risk stratified based on the degree of organ involvement and high‐risk cytogenetic features. Currently, the only FDA‐approved first‐line therapy for AL amyloidosis is a combination regimen of daratumumab, cyclophosphamide, bortezomib, and dexamethasone (DaraCyborD) with a goal of achieving a very good partial response (VGPR) after 4‐6 cycles of treatment. Autologous stem cell transplant can be considered in selected cases, although there is no robust evidence of superiority over chemotherapy alone. In the relapsed/refractory setting, numerous promising therapies are still under investigation including venetoclax especially for patients with translocation t (11; 14) and chimeric antigen receptor T‐cell therapy (CART) targeting B‐cell maturation antigen (BCMA). Trial Registration: ClinicalTrials.gov identifier: NCT04270175, NCT05451771, NCT04847453, and NCT05199337
Recent progress in the therapies used for patients with Non- Hodgkin’s lymphoma (NHL) has improved survival. In 2020, 77,240 people were diagnosed with NHL. Although it accounts for 4% of all cancers, the incidence has been reported to be decreasing in the last few years.
Multiple myeloma (MM) is a hematologic cancer resulting in plasma cell proliferation in the bone marrow [1,2]. This can lead to anemia, leukopenia, increased infection risk, fractures, and kidney d...
28 October 2025 in Journal of Clinical Haematology
Treatment options for multiple myeloma (MM) have evolved significantly over the past four decades, improving overall survival (OS) through a deeper understanding of tumor biology and personalized treatment strategies. Key factors for individualizing therapy include eligibility for autologous stem cell transplantation (ASCT), disease risk stratification, patient frailty, performance status, age, and comorbidities, aiming to maximize disease control while minimizing toxicity. Current evidence supports triplet or quadruplet regimens incorporating an anti-CD38 monoclonal antibody, a proteasome inhibitor, an immunomodulatory drug, and dexamethasone, with or without ASCT, as initial therapy. Recent studies have explored whether specific regimen components can be omitted without compromising efficacy and whether maintenance therapy can be discontinued after sustained minimal residual disease (MRD) negativity for 12 months. This review examines the evolving recommendations and evidence guiding these treatment decisions.
Hodgkin’s Lymphoma (HL) affects approximately 8500 individuals annually in the United States. The 5-year relative survival rate has improved to 88.5%, driven by transformative advances in immunotherapy and precision oncology. The integration of Brentuximab vedotin (BV) and immune checkpoint inhibitors (ICIs) has redefined treatment paradigms. The phase III SWOG S1826 trial established nivolumab plus doxorubicin, vinblastine, and dacarbazine (N + AVD) as an emerging new standard for advanced-stage HL, achieving a 2-year progression-free survival (PFS) of 92% compared to 83% for BV plus AVD (HR 0.48, 95% CI: 0.33–0.70), with superior safety, particularly in patients over 60. In relapsed/refractory HL, pembrolizumab outperforms BV, with a median PFS of 13.2 versus 8.3 months (HR 0.65, 95% CI: 0.48–0.88), as demonstrated in the KEYNOTE-204 trial. Emerging strategies, including novel ICI combinations, minimal residual disease (MRD) monitoring via circulating tumor DNA (ctDNA), and artificial intelligence (AI)-driven diagnostics, promise to further personalize therapy. This review synthesizes HL’s epidemiology, pathogenesis, diagnostic innovations, and therapeutic advances, highlighting the role of precision medicine in addressing unmet needs and disparities in HL care.